Amira Pharmaceuticals, Inc.

Panmira Pharmaceuticals, LLC

Pharmakea, Inc.

Timothy Andrew Parr

John Howard Hutchinson

Jeffrey Roger Roppe

Thomas Jon Seiders

Nicholas Simon Stock

Jeannie M Arruda

Bowei Wang

Deborah Volkots

Brian Andrew Stearns

David Gregory Lonergan

Kevin Duane Bunker

Yen Truong

Jill Melissa Scott

Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.

Heterocyclic vinyl autotaxin inhibitor compounds

Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.

Autotaxin inhibitors and uses thereof

Vinyl autotaxin inhibitor compounds

Heterocyclic autotaxin inhibitors and uses thereof

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Lysophosphatidic acid receptor antagonists

Antagonists of lysophosphatidic acid receptors

Described herein are heteroaryl compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGDreceptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

[object Object]

Polycyclic antagonists of lysophosphatidic acid receptors

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGDreceptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

Growing community of inventors

La Mesa, CA, United States of America

Timothy Andrew Parr